Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014: New Research Report Available at Fast Market Research
New Pharmaceuticals market report from Global Markets Direct: "Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014"
Boston, MA -- (SBWire) -- 04/16/2014 --Global Markets Direct's, 'Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H1 2014', provides an overview of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)'s therapeutic pipeline.
This report provides comprehensive information on the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and special features on late-stage and discontinued projects.
View Full Report Details and Table of Contents
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
- The report provides a snapshot of the global therapeutic landscape of Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Companies Mentioned in this Report: Bristol-Myers Squibb Company, Genzyme Corporation, Johnson & Johnson, Boehringer Ingelheim GmbH, F. Hoffmann-La Roche Ltd., Amgen Inc., Sanofi, AstraZeneca PLC, Eli Lilly and Company, GlaxoSmithKline plc, Seattle Genetics, Inc., Genentech, Inc., medac GmbH, Merck & Co., Inc., Gamida Cell Ltd., Generex Biotechnology Corporation, Plexxikon Inc., BioLineRx, Ltd., MediGene AG, Bio-Path Holdings, Inc., Egenix, Inc., Millennium Pharmaceuticals, Inc., Novartis AG, BioMarin Pharmaceutical Inc., Eisai Co., Ltd., Pfizer Inc., Sunesis Pharmaceuticals, Inc., Astex Pharmaceuticals, Inc., Teva Pharmaceutical Industries Limited, Cell Therapeutics, Inc., Cyclacel Pharmaceuticals Inc., Celgene Corporation, Onyx Pharmaceuticals, Inc., Incyte Corporation, Merck KGaA, 4SC AG, EntreMed, Inc., Celldex Therapeutics, Inc., Immunomedics, Inc., Ariad Pharmaceuticals, Inc., Lorus Therapeutics Inc., MEI Pharma, Inc., OXiGENE, Inc., Critical Outcome Technologies Inc., Topotarget A/S, Xenetic Biosciences plc, JW Pharmaceutical Corporation, Resverlogix Corp., Threshold Pharmaceuticals, Inc., Synta Pharmaceuticals Corp., BioAlliance Pharma SA, Sareum Holdings plc, Innate Pharma SA, Oscotec Inc., Stem Cell Therapeutics Corp., Cellerant Therapeutics, Inc., Antigen Express, Inc., Chroma Therapeutics Ltd., Colby Pharmaceutical Company, Ambit Biosciences Corporation, Actinium Pharmaceuticals, Inc., Philogen S.p.A., Oxford BioTherapeutics Ltd, BioMAS Ltd., Oncodesign SA, ERYtech Pharma, Celator Pharmaceuticals, Inc., Altor BioScience Corporation, Ascenta Therapeutics, Inc., Coronado Biosciences, Inc., Agios Pharmaceuticals, Inc., MacroGenics, Inc., Arno Therapeutics, Inc., TetraLogic Pharmaceuticals, Spirogen Ltd., Affichem, Stemline Therapeutics, Inc., Advenchen Laboratories, LLC, Onconova Therapeutics, Inc., Kainos Medicine, Inc., Syndax Pharmaceuticals, Inc., NovaLead Pharma Pvt. Ltd., Esperance Pharmaceuticals, Inc., Trillium Therapeutics Inc., SBI Biotech Co., Ltd., Tragara Pharmaceuticals, Inc., Cellceutix Corporation, Kiadis Pharma B.V., Bellicum Pharmaceuticals, Inc., KaloBios Pharmaceuticals, Inc., AB Science, Aprea AB, Kinex Pharmaceuticals, LLC, OncoImmune, Inc., CureTech Ltd., GlycoMimetics, Inc., Janssen Biotech, Inc., Merus B.V., AIMM Therapeutics B.V., Cantex Pharmaceuticals, Inc., Cancer Therapeutics CRC Pty Ltd, Interprotein Corporation, EpiZyme, Inc., Targa Therapeutics Corp., NuCana BioMed Limited, Sentinel Oncology Limited, Otsuka Holdings Co., Ltd., Genosco, BerGenBio AS, Advancell, Igenica, Inc., Selvita S.A, Karyopharm Therapeutics, Inc., EntreChem, S.L., AROG Pharmaceuticals LLC, Inbiopro Solutions Pvt. Ltd., ImmunGene, Inc., Conkwest, Inc., Cantargia AB, Immune Pharmaceuticals, Inc., Formula Pharmaceuticals, Inc., Tolero Pharmaceuticals, Inc., AbbVie Inc., SpectraMab GmbH, Pharmedartis GmbH, SYNIMMUNE GmbH
About Fast Market Research
Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget. For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.
Browse all Pharmaceuticals research reports at Fast Market Research
You may also be interested in these related reports:
- Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) - Pipeline Review, H2 2013
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H1 2014
- Acute Pain - Pipeline Review, H1 2014
- T-Cell Leukemia - Pipeline Review, H1 2014
- Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia) - Pipeline Review, H2 2013
- Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) - Pipeline Review, H1 2014
- Chronic Myelocytic Leukemia (CML, Chronic Myeloid Leukemia) Global Clinical Trials Review, H1, 2014
- Relapsed Chronic Lymphocytic Leukemia (CLL) - Pipeline Review, H1 2014
- Acute Lymphocytic/Lymphoblastic Leukemia Therapeutics Market - (Pipeline Forecast & Market Forecast in G8 Countries) (2011 - 2020)
- Acute Promyelocytic Leukemia - Pipeline Review, H2 2013
Media Relations Contact
Director of Marketing
Fast Market Research, Inc.
View this press release online at: http://rwire.com/493644